FDA's Gutierrez Provides Additional Clarity Regarding Oversight of DTC Genomics Firms
May 19, 2010
FDA's Gutierrez Provides Additional Clarity Regarding Oversight of DTC Genomics Firms
"The fact is that Pathway's bold move to make themselves noticed achieved its end and brought them to our attention," an FDA official told Pharmacogenomics Reporter.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- DTC Genomics Gets Time Before FDA as Agency Considers Regulatory Strategy
July 21, 2010 / Pharmacogenomics Reporter - Texas Congressman Drafts Bill to Keep Lab Test Oversight out of 'FDA's Lap,' Expand Authority of CMS
October 19, 2011 / Pharmacogenomics Reporter - DTC Genomics Firms Say They Want to Comply with FDA Regs but Maintain Direct Access
March 16, 2011 / Pharmacogenomics Reporter - CDC Advises Docs to Inform Patients of Limitations of DTC Gene Scans
August 11, 2010 / Pharmacogenomics Reporter - In Wake of 'Flawed' GAO Report, Consumer Genomics Firms Call for Regulatory Plan for DTC Industry
July 28, 2010 / Pharmacogenomics Reporter